DavendraPratap SinghSohalMDMPH

Oncology • Cincinnati, OH

Gastrointestinal Cancer, Hematologic Oncology

Professor of Medicine; Associate Director for Clinical Research at the University of Cincinnati Cancer Center

Join to view full profile

Dr. Sohal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sohal's full profile

Already have an account?

Office
3199 Highland Ave
Cincinnati, OH 45219
Phone+1 513-475-8500

Fax+1 513-584-4281

Summary

Dr. Davendra Sohal is an oncologist at the University of Cincinnati. His clinical focus is gastrointestinal malignancies, and his research focus is clinical trials, including Phase I trials, precision oncology trials, and multidisciplinary studies.

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2009 - 2012
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2005 - 2008
University of Alabama at BirminghamMPH, Epidemiology and Biostatistics, 2003 - 2005
All India Institute of Medical SciencesClass of 2002, MD

Certifications & Licensure

OH State Medical License 2012 - 2026
PA State Medical License 2009 - 2012
NY State Medical License 2008 - 2010
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
LDE225 for Patients With PTCH1 or SMO Mutated Tumors Start of enrollment: 2014 Feb 01
Terminated
Phase 2
BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24
Terminated
Phase 2
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Start of enrollment: 2016 Jan 06
Completed
Phase 2
A Study of ABTL0812 in Pancreatic Cancer Start of enrollment: 2021 Apr 26
Suspended
Phase 1, Phase 2
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors Start of enrollment: 2024 Jan 08
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

348 citations
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
John D. Gordan, Erin B. Kennedy, Ghassan K. Abou-Alfa, Muhammad Shaalan Beg, Steven Brower
Journal of Clinical Oncology. 2020-11-16
46 citations
Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Steven G Waguespack, Alexander Drilon, Jessica J Lin, Marcia S Brose, Ray McDermott
European Journal of Endocrinology. 2022-04-29
295 citations
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry...
Michael J. Pishvaian, Edik M. Blais, Jonathan R. Brody, Emily Lyons, Patricia DeArbeloa
The Lancet. Oncology. 2020-04-01

Lectures

A pilot clinical trial of p53/p16-independent epigenetic therapy for pancreatic ductal adenocarcinoma (PDA).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenoc...
2019 ASCO Annual Meeting - 6/1/2019
Accelerating advanced precision medicine through a harmonized data exchange platform and research consortium (PMEC).
2019 ASCO Annual Meeting - 6/1/2019
SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Press Mentions

University of Cincinnati Researcher Receives Catalyst Research Award to Further Cancer ResearchDecember 7th, 2021
Pre-Surgery Chemotherapy Is Possible for Early Stage Pancreatic Cancer PatientsJanuary 21st, 2021
IP Paclitaxel Add-on Promising in Pancreatic CancerJuly 14th, 2020
Join now to see all